Kornimate/medical-research-clean huggingface dataset:
can high-flow oxygen therapy improve oxygenation during exercise in ild patients?

Conditions: Intersticial Lung Disease

Summary: objectives: 1.- to compare the level of oxygenation achieved during muscular training with conventional oxygen systems (nasal cannulas) versus nasal high-flow oxygen therapy. 2.-to compare benefits achieved with both systems, in terms of: level of exercise during training; effort tolerance in the 6 minutes walking test (6mwt); improvement of dyspnoea and health-related quality of life (hrqol). and analyse the effects of nasal high-flow oxygen therapy on the acute exercise in a subgroup of patients. method: multicentric randomized clinical trial. patients with ild in fibrotic phase who present oxygen desaturation during 6mwt (spo2 mean ≤ 85%) will be included consecutively. will be randomized in two groups: ild patients with conventional oxygen (epidoc) and ild patients with nasal high-flow oxygen therapy (epidoaf). both groups will perform a pulmonary rehabilitation program. oxygen will be titrated respectively to flow and fio2 needed to maintain spo2 ≥ 90% during training with both systems. evaluation measures: spo2 during training in both groups; dyspnoea (mmrc scale and crq dyspnoea); exercise capacity (6mwt) and hrqol (self- administered kbild questionnaire and sf36). in a subgroup of patients will be compared time of endurance exercise to evaluate the effects of nasal high-flow oxygen therapy in the acute exercise.


Eligibility criteria:
inclusion criteria: * age \> 30 years old * diagnostic of ild according to the national and international guidelines 23 * being clinically stable the previous 4 weeks * acceptance to participate in the trial exclusion criteria: * have been enrolled in a pr program in the last previous 6 months * respiratory diseases other than ild or severe comorbidities * osteoarticular diseases which don't allow training * end-stage ild, treatment with opiates or survival \< 6 months * cognitive alterations that preclude colaboration
clinical study to evaluate safety and efficacy of bmmnc in retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: retinitis pigmentosa is an eye disease in which there is damage to the retina. the retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain.autologous bone marrow derived mono nuclear stem cell (bmmncs) is used for this condition .

this study will involve about 8 visits over 1½ years .each participant will be enrolled in study as per inclusion and exclusion criteria .informed consent will be taken from subject before including in study. subject will be underwent for specific tests of the participant's vision and health. these visits may include visual exams, blood draw for laboratory testing, brief medical history and exam, and occasionally a questionnaire (survey), in addition to the visit for the surgical procedures. the primary outcome for this study will be a visual acuity score after one year of stem cell therapy . follow-up visits will be required regularly to determine the effectiveness of autologous bone marrow derived mono nuclear stem cell (bmmncs) in rp.

Eligibility criteria:
inclusion criteria: * age 18-65 * diagnosis of retinitis pigmentosa * willingness to undergo bone marrow and umbilical cord derived mesenchymal stem cell transplantation. * to give an informed consent as well as sign the required informed consent form (icf) for the study. * willingness to regularly visit the hospital / clinic for follow up during the follow up period / on prior agreed time points as per the protocol. exclusion criteria: * positive test results for hiv and aids complex ,hcv (hepatitis c virus ), hbsag and syphilis * women who are pregnant or lactating * complications of diabetic retinopathy.

Keywords: retinitis pigmentosa bone marrow stem cell bmmnc
effect of pregabalin on the postoperative analgesia in rfa of focal lesions in the liver

Conditions: Hepatocellular Cancer

Summary: the study aimed to investigate the preemptive analgesia efficacy of of preemptive pregabalin for the postoperative pain management after radiofrequency ablation (rfa) of liver cancer.

our data will investigate if preemptive administration of pregabalin will have a role in reducing postoperative pain after radiofrequency ablation (rfa) of liver cancer.

Eligibility criteria:
inclusion criteria: * hcc patients, child a, b, scheduled for radiofrequency ablation of hcc. exclusion criteria: * encephalopathy, renal impairment
safety and efficacy of vanoxerine for conversion of atrial fibrillation or flutter to normal sinus rhythm

Conditions: Symptomatic Atrial Fibrillation; Atrial Flutter

Summary: evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or flutter of recent onset to normal sinus rhythm.

vanoxerine has important antiarrhythmic properties and may prove effective in converting af/afl to sinus rhythm in subjects with a history of af. this is a prospective, randomized, double-blinded, placebo-controlled, dose-modifying study in subjects who have been in symptomatic af or afl for more than 3 hours and less than 7 days as dated by symptoms, who have af/afl documented on ecg at the time of study drug administration, and who satisfy the inclusion and exclusion criteria. the primary objectives of the trial are to evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo following oral administration.

Eligibility criteria:
inclusion criteria: * provide written informed consent, * male or female 18 years of age or greater; women of child bearing potential must use adequate contraception * symptomatic af/afl for more than 3 hours and less than 7 days (168 hours), as dated by symptoms * af/afl documented by ecg at the start of study drug administration exclusion criteria: * systolic blood pressure \<100 mmhg. * average heart rate \<50 bpm. * average qtcf (fridericia correction) \>440 ms. * average qrs interval \>140 ms. * paced atrial or ventricular rhythm on ecg. * serum potassium \<3.5 meq/l (may be corrected prior to randomization). * received another intravenous class i or class iii antiarrhythmic drug within prior 3 days. * received amiodarone (oral or iv) in prior 3 months. * clinical evidence or history of acute coronary syndrome within 30 days prior to randomization. * aortic stenosis with aortic valve area equal to or less than 1.0 cm2. * rheumatic mitral stenosis with valve area of \<1.5 cm2. * untreated hyperthyroidism. * acute pericarditis. * af/afl as a result of surgery within the last 7 days * history of failed electrical cardioversion * history of polymorphic ventricular tachycardia (pvt, e.g. torsades de pointes). * history or family history of long qt syndrome. * history of ventricular tachycardia requiring drug or device therapy. * history of nyha heart failure class 3 or 4 or recent (within 1 month) onset of heart failure not related to rapid ventricular response af. * ejection fraction (ef) of 35% or less.

Keywords: vanoxerine atrial fibrillation atrial flutter a-fib
save the ovaries - surgical management of simple ovarian cysts in children and adolescents

Conditions: Ovarian Cyst Benign

Summary: the purpose of this study is to evaluate which operative technique should be used for managing simple ovarian cysts in girls and adolescents. the two techniques that are being compared are laparoscopic cyst enucleation and laparoscopic cyst deroofing. the investigators will assess the effect of both techniques on the ovarian reserve and the risk of cyst recurrence.


Eligibility criteria:
inclusion criteria: * symptomatic simple cysts ≥ 4 cm with indication for surgical intervention * asymptomatic cysts ≥ 4 cm, with surgical indication due to persistence or increase in size * asymptomatic cysts ≥ 4 cm with other pathology as surgical indication, if known preoperatively * age 12 months - 18 years * parents/legal custodian and patient give consent, for patients unable to consent due to their health condition or developmental status they show no signs of unwillingness to participate * symptomatic simple cysts ≥ 4 cm with indication for surgical intervention on both ovaries (each ovary will count as one) exclusion criteria: * neonatal ovarian cysts (age \<12 months) * age \>18 years * complex cysts (with solid components, e.g., teratoma, risk or suspicion of malignancy) * paratubar/paraovarian cysts * medical reason that precludes cyst enucleation (e.g. severe coagulopathy) * neither signed informed consent form or inadequate german, french or english language skills to give informed consent

Keywords: ovarian cyst laparoscopy child
management of sexual dysfunction with bioresonance technique

Conditions: Sexual Dysfunction; Erectile Dysfunction; Premature Ejaculation

Summary: bioresonance is the big promise of the medical technology of the future because it stimulates the self-regenerating system of the body by affecting the body's most essential procedures. the big advantage is that its multiple and there are no harmful side effects. this therapy teaches something to the body what in a younger and healthier state it had already bioresonance is based on the scientific principle that metabolism within cells is influenced by one's electromagnetic field. we start to use bioresonance technology in management of erectile dysfunction , premature ejaculation, decreased libido.


Eligibility criteria:
inclusion criteria: * erectile dysfunction premature ejaculation decreased libido exclusion criteria: * nil

Keywords: erectile dysfunction, sexual dysfunction, bioresonance
visual perception in preterm infants

Conditions: Pediatrics

Summary: we aim to increase our knowledge of the impact of preterm birth on the maturation of the visual and auditory systems and on the development of multisensory perception specifically, we aim to evaluate the preterm infants' capabilities of detection and discrimination of different visual and auditory stimuli according to gestational age, post menstrual age and the duration of the postnatal life. a secondary aim is to compare this competencies in preterm and full term control art term equivalent age. the final aim is to optimize the hospital environment in order to make it correspond to the expectations and sensory abilities of very preterm infants. our hypothesis is that preterm birth exposes the infants to numerous atypical stimuli which could accelerate the processes of sensory maturation


Eligibility criteria:
inclusion criteria: * newborn less than 32 weeks pma hospitalized in the hospital of hautepierre, strasbourg, france) * consent obtained from both parents * social insurance coverage exclusion criteria: * any known malformation * brain lesions discovered on brain ultrasound (intra-ventricular hemorrhage grade iii or iv periventricular leukomalacia). * unstable clinical state * retinopathy of prematurity stage\> 2 or in zone 1 * family history of abnormal color vision. * abnormalities in auditory testing * transfer to another hospital expected before 40 week pma
international collaboration of comprehensive physiologic assessment

Conditions: Stable Angina; Unstable Angina; Non-ST Elevation Myocardial Infarction; ST-segment Elevation Myocardial Infarction

Summary: the current study evaluated prognostic implication of comprehensive physiologic assessment using fractional flow reserve, coronary flow reserve (cfr) and index of microcirculatory resistance (imr).

the patient-level data was gathered from 3 nations (korea, japan, spain). the total 1397 patients (1694 vessels) data was collected from 5 university hospitals in korea (seoul national university hospital, samsung medical centre, inje university ilsan paik hospital, keimyung university dongsan medical centre, and ulsan university hospital, korea) and tsuchiura kyodo general hospital, ibaraki, japan, and hospital clinico san carlos, madrid, spain. standardized form of data collection sheet was used and all study adopted standardized definition of patient's baseline characteristics, clinical outcomes, and physiologic data. in case of acute coronary syndrome (unstable angina, non-st-segment elevation myocardial infarction, and st-segment elevation myocardial infarction), only non-culprit vessel was included in the data. primary outcome is patient- and vessel-oriented composite outcome at 5 years.

Eligibility criteria:
inclusion criteria: - patients who underwent clinically indicated invasive coronary angiography and measurements of ffr, cfr, and imr for at least 1 coronary artery exclusion criteria: * patients with hemodynamic instability * left ventricular dysfunction * culprit vessel of acute coronary syndrome

Keywords: fractional flow reserve myocardial ischemia coronary artery disease coronary flow reserve index of microcirculatory resistance prognosis percutaneous coronary intervention
effect of combined imt and cpap in pulmonary rehabilitation for copd

Conditions: Pulmonary Rehabilitation

Summary: inspiratory muscle training(imt) was one of the widely used pulmonary rehabilitation method in copd patients.however, when the respiratory muscles are fatigue without sufficient rest, imt may increase muscle fatigue and aggravate muscle damage. noninvasive positive pressure ventilation (nppv) is another important strategy of pulmonary rehabilitation which could overcome airway resistance and reduce respiratory work, improve respiratory muscle fatigue. therefore, the purpose of this study was to explore the effective of the "imt - nppv sequential" rehabilitation method, that is, first inspiratory muscle training, followed by respiratory muscle resting (non-invasive positive pressure ventilation).

exploring the effects of the new rehabilitation method of "imt - nppv sequential", comparing with the single rehabilitation strategy such as inspiratory muscle training and non-invasive positive pressure ventilation.

Eligibility criteria:
inclusion criteria: * patients with pulmonary function test of forced expiratory volume at one second (fev1)/forced vital capacity(fvc) \< 70% after inhalation of bronchial dilation agent. patients in a clinically stable state. exclusion criteria: * patients were excluded if they had other respiratory diseases ,or evidence of pneumothorax or mediastinal emphysema and pacemaker installed. patients with acute cardiovascular event and severe cor pulmonale. patients with poor compliance. an other causes of diaphragmatic dysfunction

Keywords: imt,nppv,pulmonary rehabilitation
attention training for covid-19 related distress

Conditions: Anxiety

Summary: the study aims to test whether attention training (attention bias modification or attention control training) reduces distress or covid-19 related anxiety compared to a neutral condition.


Eligibility criteria:
inclusion criteria: * covid-19 anxiety syndrome scale \> 7 and/or covid-19 related loss exclusion criteria: * does not speak english fluently
efficacy and toxicity of increasing doses of idarubicin, cytarabine and g-csf in acute myeloid leukemia

Conditions: Di Novo Acute Myeloid Leukemia

Summary: while several studies have been reported with increasing doses of daunorubicin in the first line treatment of acute myeloid leukemia (aml), there is no similar experience with idarubicin as initial treatment of aml. as idarubicin is the most common treatment used for aml, it is needed to find the optimal dose for the combination of idarubicin, cytarabine and g_csf, to explore if this combination improves the outcomes of current treatments for aml. the aim of this dose-finding study is to find the optimal dose for the combination of idarubicin, cytarabine and g-csf that could improve the response rate, reduce relapse and improve survival of patients with primary acute myeloid leukemia. this could be a significant advance in a field where treatment outcomes have stabilized in the last 15 years. this study will be the basis for further prospective, randomized, multicenter trial comparing idarubicin maximum tolerated dose, compared to standard treatment with idarubicin and cytarabine, including raising both arms in g-csf. the dose of 12 mg/m2 will be administered as control arm in this future randomized study, which will investigate the benefit of enhanced dose identified as optimal in this phase ii pilot study.


Eligibility criteria:
inclusion criteria: informed consent signature patients with newly diagnosed aml, classified according to who criteria. age more than or equal to 18 and less than or equal to 70 years. exclusion criteria: patients previously treated with chemotherapy for their aml other than hydroxyurea. acute promyelocytic leukemia with t (15; 17). blast crisis of chronic myeloid leukemia. leukemias that appear after other myeloproliferative neoplasms. leukemias ensuing myelodysplastic syndromes after more than 6 months. presence of other malignancies in activity. aml secondary to chemo-radiotherapy treatment for other malignancies. abnormal renal and hepatic function, with creatinine value and / or bilirubin 2 times the normal limit value, except where the alterations are attributable to leukemia. patients with markedly reduced ejection fraction (less than 45%), symptomatic heart failure, or both of the normal value of the center. patients with serious concomitant psychiatric or neurological disease. hiv-positive. pregnancy or breastfeeding

Keywords: acute myeloid leukemia cetlam idarubicin
the effects of nsaids on bone metabolism following exercise

Conditions: Bone Resorption; Stress Fracture; Bone Injury

Summary: the purpose of this study is to determine the effects of a single dose of non-steroidal anti-inflammatory drugs on post-exercise markers of bone and muscle metabolism.

this protocol intends to determine how consuming a single dose of a non-steroidal anti-inflammatory drug (nsaid) affects circulating bone metabolism biomarkers and markers of damage skeletal muscle in response to a bout of plyometric exercise. this will be accomplished using a four trial, placebo-controlled crossover design with trials examining ibuprofen, celecoxib, flurbiprofen and placebo. these particular nsaids were chosen because of their widespread use in military populations and differing molecular mechanisms, which could cause differing effects on bone and muscle. two hours after of consuming a single dose of an nsaid, participants will perform 10 sets of 10 plyometric jumps to induce a mechanical loading stimulus the bone and muscle tissues. blood, urine, and muscle biopsy samples will be collected before and up to four hours after exercise. biomarkers representing bone and muscle metabolism will determine the magnitude of adaptive responses to plyometric exercise while using nsaids.

Eligibility criteria:
inclusion criteria: * must currently exercise at least 2 times per week * must be willing to discontinue the use of nutritional supplements, alcohol and nicotine during each study period (4 trials of 5 consecutive days each), unless approved by pi * must be willing to refrain from taking nsaids and similar medications during the course of the study (other than those given by the study team) * weigh at least 110 lbs and have a hemoglobin of 12.5 g/dl or higher exclusion criteria: * known allergic reaction to any nsaid type medication * history of gastrointestinal disorders/discomfort associated with or which may be aggravated with nsaid use * history or known gastric ulcer * history of endocrine disorders (e.g., diabetes, uncontrolled thyroid dysfunction, hypoparathyroidism, or hyperparathyroidism) * history of bone-modifying disorder (e.g., osteogenesis imperfecta, osteoporosis, or rickets) * diagnosed bone fracture within last 6 months * history of cardiovascular or renal diseases * pregnant or lactation in the last 6 months * currently taking or history of routine use of medications known to affect bone or calcium metabolism (e.g., thiazide diuretics, bisphosphonates, oral steroids) * history of back or shoulder injury which may be aggravated by exercise * blood donation within 8 weeks of the study * current physical illness or injury limiting physical activity * known allergy to lidocaine
radiographic migration analysis of the insignia hip stem

Conditions: Hip Implant; Hip Replacement in Osteoarthritis Patients; Migration of Implant

Summary: the purpose of this study is to assess the migration pattern of the insignia hip stem using radiostereometric analysis (rsa for short) and computed tomography (ct). only patients with degenerative joint disease requiring primary total hip replacement will be asked to participate. the other purpose is to assess if there are any differences between the gold-standard rsa-measured migration and ct-rsa-measured migration. the clinical outcomes will be measured using joint function and patient satisfaction questionnaires. approximately thirty patients will be enrolled onto the study.

this is a single-centre, non-randomized, non-controlled trial of patients undergoing primary total hip arthroplasty using the insignia hip stem. patients will undergo rsa and ct-rsa imaging and analyses to identify migration of the femoral stem with respect to the adjuvant bone during the first 2 post-operative years. the primary outcome of this study is to determine if femoral stem stability is achieved between 6-12 month and 12-24 month post-operative intervals.

Eligibility criteria:
inclusion criteria: * symptomatic osteoarthritis of the hip indicating primary total hip arthroplasty - aged 21 years or older * patients willing and able to comply with follow-up requirements and self-evaluations * ability to give informed consent exclusion criteria: * active or prior infection * medical condition precluding major surgery * medical condition with less than 2 years life expectancy * overhanging pannus (direct anterior approach) * prior surgery of the hip involving implantation of hardware (i.e., hemiarthroplasty, internal fixation, pelvic reconstruction near the acetabulum requiring removal) * skin condition on the area of incision * multi-level lumbar spine fusion * ankylosing spondylolithesis * shortening osteotomy through the femur

Keywords: insignia rsa total hip replacement